University of Texas Texas AM Investment Management Co. Takes $1.02 Million Position in United Therapeutics Corporation $UTHR

University of Texas Texas AM Investment Management Co. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 2,095 shares of the biotechnology company’s stock, valued at approximately $1,021,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. Darwin Global Management Ltd. bought a new position in United Therapeutics in the 3rd quarter valued at $317,617,000. Norges Bank bought a new stake in shares of United Therapeutics during the fourth quarter worth $293,418,000. Dimensional Fund Advisors LP lifted its position in shares of United Therapeutics by 3.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 528,210 shares of the biotechnology company’s stock worth $257,405,000 after purchasing an additional 15,394 shares during the last quarter. Baillie Gifford & Co. purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $157,390,000. Finally, Victory Capital Management Inc. grew its holdings in shares of United Therapeutics by 108.1% in the fourth quarter. Victory Capital Management Inc. now owns 228,383 shares of the biotechnology company’s stock worth $111,280,000 after purchasing an additional 118,628 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research note on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 634,468 shares of company stock worth $357,970,302 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

UTHR stock opened at $549.57 on Tuesday. The business has a 50-day moving average price of $566.45 and a 200 day moving average price of $522.10. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a market capitalization of $23.33 billion, a P/E ratio of 20.29, a PEG ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the firm posted $6.63 earnings per share. The company’s revenue was down 1.6% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.